The early-stage biotech Neuron23 has appointed Dr. Sam Jackson as its first chief medical officer.
South San Francisco, California–based Neuron23 specializes in developing precision medicines for genetically-defined neurological and immunological diseases.
Jackson is a board-certified emergency physician with fellowship training in medical toxicology.
“I am thrilled to welcome Dr. Jackson to our growing Neuron23 leadership team,” said Nancy Stagliano, CEO of Neuron23, in a statement.
Neuron23 is working to advance NEU-723, a brain-penetrant LRRK2 inhibitor for Parkinson’s disease, into clinical trials.
Previously, Jackson worked as the senior vice president and chief medical officer of Alector (Nasdaq:ALEC), a biopharma developing therapies for neurodegeneration diseases.
Neuron23 was founded in 2018 to focus on neurodegenerative diseases, neuroinflammatory diseases and systemic autoimmune and inflammatory diseases.
In late March 2022, the company closed a $100 Million Series C financing round and selected NEU-723 as a clinical candidate for Parkinson’s.
Filed Under: Neurological Disease